Noticias

Ability Pharmaceuticals to Present at the Biotech Showcase Event (a Satellite to JP Morgan Healthcare Conference) in San Francisco, January 7-9, 2013.

23 de diciembre de 2012

Ability Pharmaceuticals, SL announced today that Carles Domenech, PhD, Chief Executive Officer and co-Founder, will be presenting at the Biotech Showcase Conference on Tuesday, January, 8, 2013 at the Parc 55 Wyndham in San Francisco, California (USA). The conference takes place during the course of JP Morgan Healthcare conference, one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week which is widely viewed as setting the tone for the coming year.

Dr. Domènech will present a company overview and will pursuit Ability Pharmaceuticals’s ongoing contacts with the industry and investors.

About Ability Pharmaceuticals
 
Ability Pharmaceuticals is a drug research and development company founded in 2009 with headquarters in Bellaterra (Barcelona, Catalonia, Spain) at Research Park of the Autonomous University of Barcelona and a planned US development office in Boston, Massachusetts (USA) in 2013.
 
Ability Pharmaceuticals develops highly differentiated innovative cancer drugs, with a novel mechanism of action, called Lipid Analog Therapeutics. The company has two drug candidates in development: ABTL0812, which is completing preclinical development, with planned phase Ib clinical trials in lung cancer and pancreatic cancer starting in spring 2013; and ABTL1014, expected to start preclinical development in 1Q 2013.

ÚLTIMAS NOTICIAS

12.09.2019

Noticias

AbilityPharma capta 3,5 millones de € en una ronda de financiación para finalizar el ensayo fase 2 oncológico actual y licenciar ABTL0812 a una farmacéutica internacional + info
31.05.2019

Noticias

Ability Pharmaceuticals anuncia la presentación de los primeros resultados de ABTL0812 como a terapia de primera línea en pacientes con cáncer de endometrio o de pulmón en el Annual Meeting ASCO 2019 + info
04.02.2019

Noticias

AbilityPharma anuncia la aprobación en China de un estudio clínico en cáncer pancreático con ABTL0812 + info
30.01.2019

Noticias

Ability Pharmaceuticals asiste al BIOMED EVENT® by INVEST SECURITIES y al Cholangiocarcinoma Foundation Annual Conference + info
05.12.2018

Noticias

AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre + info
07.11.2018

Noticias

Ability Pharmaceuticals anuncia la Designación de Medicamento Huérfano por parte de la FDA de ABTL0812 para el tratamiento de tumores biliares + info
19.09.2018

Noticias

Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info
24.08.2018

Noticias

Desde AbilityPharma estamos muy contentos de anunciar el inicio de una campaña de crowdfunding a través de Capital Cell + info
19.02.2018

Noticias

AbilityPharma anuncia la aprobación por parte de la FDA (Estados Unidos) del ensayo clínico de fase 1/2 con ABTL0812 en pacientes con cáncer de páncreas + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG